CA2666293C — Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders
Assigned to Vanda Pharmaceuticals Inc · Expires 2017-01-10 · 9y expired
What this patent protects
This invention provides the use of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder. More specifically, it discloses the use of (1R-tra…
USPTO Abstract
This invention provides the use of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder. More specifically, it discloses the use of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide (MA-1) for the preparation of a pharmaceutical composition for the treatment of a circadian rhythm disorder or a sleep disorder, the pharmaceutical composition being formulated for orally administering MA-1 to the subject suffering such disorder in an amount of about 20 mg to about 50 mg per day.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.